We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Aligos Therapeutics Inc
4 own
12 watching
Current Price
$1.19
$0.06
(5.31%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
51.1M
52-Week High
2.41
52-Week Low
0.8401
Average Volume
0.16M
Dividend Yield
--
P/E Ratio
--
Market Capitalization51.1M52-Week High2.4152-Week Low0.8401Average Volume0.16MDividend Yield--P/E Ratio--What does the Aligos Therapeutics Inc do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More
How much money does Aligos Therapeutics Inc make?
News & Events about Aligos Therapeutics Inc.
Benzinga
2 months ago
read more...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, ...
Globe Newswire
4 months ago
Final cohort of Phase 1 study projected to be complete in H1 2023 Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT SOUTH SAN FRANCISCO, ...
Frequently Asked Questions
Frequently Asked Questions
What is Aligos Therapeutics Inc share price today?
Can Indians buy Aligos Therapeutics Inc shares?
How can I buy Aligos Therapeutics Inc shares from India?
Can Fractional shares of Aligos Therapeutics Inc be purchased?
What are the documents required to start investing in Aligos Therapeutics Inc stocks?
What is today’s traded volume of Aligos Therapeutics Inc?
What is today’s market capitalisation of Aligos Therapeutics Inc?
What is the 52-Week High and Low Range of Aligos Therapeutics Inc?
What percentage is Aligos Therapeutics Inc down from its 52-Week High?
What percentage is Aligos Therapeutics Inc up from its 52-Week Low?
Current Price
$1.19
$0.06
(5.31%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.